Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Gilbert Zvikomborero Murimwa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7948-0980; OpenAlex author ID A5032525529. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 9

  1. Combined Association of Time to Treatment, Guideline Concordance, and Neighborhood Vulnerability with Localized Colon Cancer, Non-small-cell Lung Cancer, and P… Co-author DOI 10.1245/s10434-026-19760-5↗
  2. SMAD4 Deficiency Promotes Pancreatic Cancer Progression and Confers Susceptibility to TGFβ Inhibition. Co-author DOI 10.1158/0008-5472.can-24-1970↗
  3. Factors associated with failure to operate and its impact on survival in early-stage pancreatic cancer. Co-author DOI 10.1002/jso.27357↗
  4. Implications of the interaction between travel burden and area deprivation for patients with pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2023.06.013↗
  5. Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter? Co-author DOI 10.1245/s10434-023-13308-7↗
  6. ASO Author Reflections: Expanding Guideline Concordant Care: The Time for a National Accreditation Program for Pancreatic Cancer is Now. Co-author DOI 10.1245/s10434-023-13376-9↗
  7. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2022.04.011↗
  8. Neutrophil to lymphocyte ratio, not platelet to lymphocyte or lymphocyte to monocyte ratio, is predictive of patient survival after resection of early-stage pa… Co-author DOI 10.1186/s12885-020-07182-9↗
  9. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. Co-author DOI 10.21037/jgo.2017.09.13↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patricio Marcelo Polanco · 5 shared papers, 2023–2026 · strength 1.10
  2. Herbert J. Zeh · 4 shared papers, 2023–2026 · strength 0.86
  3. Adam Charles Yopp · 3 shared papers, 2023 · strength 0.56
  4. Matthew R. Porembka · 2 shared papers, 2023 · strength 0.34
  5. Sam C. Wang · 2 shared papers, 2023 · strength 0.34
  6. Huocong Huang · 2 shared papers, 2022–2025 · strength 0.34
  7. Rolf A. Brekken · 2 shared papers, 2022–2025 · strength 0.34
  8. Jason B. Fleming · 2 shared papers, 2020–2025 · strength 0.31
  9. Muhammad Sohaib Khan · 1 shared paper, 2026 · strength 0.30
  10. Cecilia Grace Ethun · 1 shared paper, 2025 · strength 0.20
  11. Aatur Dilip Singhi · 1 shared paper, 2025 · strength 0.20
  12. José M. Pimiento · 2 shared papers, 2018–2020 · strength 0.19
  13. Mokenge Peter Malafa · 2 shared papers, 2018–2020 · strength 0.19
  14. Pamela Joy Hodul · 2 shared papers, 2018–2020 · strength 0.19
  15. Caitlin A. Hester · 1 shared paper, 2023 · strength 0.17
  16. Sören Müller · 1 shared paper, 2022 · strength 0.14
  17. Ravikanth Maddipati · 1 shared paper, 2022 · strength 0.14
  18. David Roife · 1 shared paper, 2020 · strength 0.11
  19. David T. Pointer · 1 shared paper, 2020 · strength 0.11
  20. Benjamin Daniel Powers · 1 shared paper, 2020 · strength 0.11
  21. William H. Jin · 1 shared paper, 2018 · strength 0.09
  22. Eric A. Mellon · 1 shared paper, 2018 · strength 0.09
  23. Jessica M. Frakes · 1 shared paper, 2018 · strength 0.09
  24. Sarah E. Hoffe · 1 shared paper, 2018 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.